The nurse is admitting a client to the acute care floor with methicillin-resistant S. aureus. The nurse would expect the physician to order which of the following medications for the client?

1. Abdominal surgery requires starting antibiotic therapy 4 days before surgery:

This statement is not accurate. While antibiotic prophylaxis is commonly administered before certain types of surgery to prevent surgical site infections, the timing and duration of antibiotic therapy vary depending on factors such as the type of surgery, the patient’s medical history, and institutional guidelines. However, starting antibiotic therapy four days before surgery would not be standard practice for most abdominal surgeries.

B. A reduction of intestinal bacteria lessens the possibility of postoperative infection:

This statement is correct. Neomycin, as well as other antibiotics used in bowel preparation regimens, help reduce the population of intestinal bacteria. By decreasing the bacterial load in the bowel before surgery, the risk of contaminating the surgical site with harmful bacteria during the procedure is reduced, thus lowering the likelihood of postoperative infections.

C. The bacteria found in the bowel cannot be destroyed after surgery:

This statement is incorrect. While it is true that the bowel contains a complex ecosystem of bacteria that play important roles in digestion and other physiological functions, the population of intestinal bacteria can be temporarily reduced through the use of antibiotics, such as neomycin, as part of a bowel preparation regimen before surgery.

D. Anesthesia makes the bowel resistant to an antibiotic after surgery:

This statement is not accurate. Anesthesia does not render the bowel resistant to antibiotics after surgery. However, the administration of antibiotics during surgery and postoperatively may be indicated in certain cases to prevent or treat infections, particularly if the surgical procedure involves contamination of the abdominal cavity or if the patient is at increased risk of infection.

A. The herbal product must contain only one active ingredient:

This statement is not a legal requirement contained in DSHEA. Many dietary supplements contain multiple active ingredients, such as vitamins, minerals, herbs, amino acids, and other substances. DSHEA does not mandate that dietary supplements contain only one active ingredient.

B. Effectiveness must be demonstrated by the manufacturer:

DSHEA does not require manufacturers to demonstrate the effectiveness of dietary supplements before marketing. Unlike pharmaceutical drugs, which must undergo premarket approval by the Food and Drug Administration (FDA) to demonstrate safety and efficacy, dietary supplements do not need to prove effectiveness to be marketed. Instead, manufacturers are responsible for ensuring the safety of their products and making truthful claims on product labels.

C. Dietary supplements must state that the product is not intended to diagnose, treat, cure, or prevent any disease:

This statement accurately reflects a legal requirement contained in DSHEA. Under DSHEA, dietary supplement labels must include a disclaimer stating that the product is not intended to diagnose, treat, cure, or prevent any disease. This disclaimer helps to clarify that dietary supplements are intended to support general health and well-being rather than to treat specific diseases or medical conditions.

D. Dietary supplements must be tested for safety prior to marketing:

While DSHEA requires manufacturers to ensure the safety of their dietary supplements, it does not mandate standardized premarket testing for safety by regulatory authorities. Instead, manufacturers are responsible for conducting safety assessments and ensuring that their products are safe for consumers. The FDA may take action against manufacturers if a product is found to be unsafe or if it violates regulatory requirements, but premarket testing is not a specific legal requirement under DSHEA.